PD-L1 and CD8+ TILs, as important factors of anti-tumor immune response, often determine the efficacy of anti-programmed death receptor 1 (PD-1)/PD-L1 antibodies in various solid tumors. This evidence concerns the gene CD8A and neoplasm.